Terms: = Prostate cancer AND NCOA2, TIF2, 10499, ENSG00000140396, NCoA-2, MGC138808 AND Clinical Outcome
4 results:
1. ncoa2 is a candidate target gene of 8q gain associated with clinically aggressive prostate cancer.
Silva MP; Barros-Silva JD; Vieira J; Lisboa S; Torres L; Correia C; Vieira-Coimbra M; Martins AT; Jerónimo C; Henrique R; Paulo P; Teixeira MR
Genes Chromosomes Cancer; 2016 Apr; 55(4):365-74. PubMed ID: 26799514
[TBL] [Abstract] [Full Text] [Related]
2. Integrative genomic profiling of human prostate cancer.
Taylor BS; Schultz N; Hieronymus H; Gopalan A; Xiao Y; Carver BS; Arora VK; Kaushik P; Cerami E; Reva B; Antipin Y; Mitsiades N; Landers T; Dolgalev I; Major JE; Wilson M; Socci ND; Lash AE; Heguy A; Eastham JA; Scher HI; Reuter VE; Scardino PT; Sander C; Sawyers CL; Gerald WL
Cancer Cell; 2010 Jul; 18(1):11-22. PubMed ID: 20579941
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic value of the androgen receptor and its coactivators in patients with D1 prostate cancer.
Mori R; Wang Q; Quek ML; Tarabolous C; Cheung E; Ye W; Groshen S; Hawes D; Togo S; Shimada H; Danenberg KD; Danenberg PV; Pinski JK
Anticancer Res; 2008; 28(1B):425-30. PubMed ID: 18383880
[TBL] [Abstract] [Full Text] [Related]
4. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer.
Agoulnik IU; Vaid A; Nakka M; Alvarado M; Bingman WE; Erdem H; Frolov A; Smith CL; Ayala GE; Ittmann MM; Weigel NL
Cancer Res; 2006 Nov; 66(21):10594-602. PubMed ID: 17079484
[TBL] [Abstract] [Full Text] [Related]
